We identified two novel amino acid polymorphisms, HLA‐DRB1 amino acid Phe in site 67 and HLA‐B amino acid Glu in site 45 associated with NPC risks. The gene discussed is HLA-DRB1; the disease is nasopharyngeal carcinoma.